Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma to Report Fourth Quarter and Year End 2015 Financial Results on March 14

NEWTON, Mass., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for...
February 25, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma to Present at Upcoming Investor Conferences

NEWTON, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for...
January 08, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma Reviews 2015 Accomplishments and Outlines Core Objectives for 2016

Ended 2015 with Between $148 Million and $149 Million in Cash, Cash Equivalents and Marketable Securities, Which the Company Believes is Sufficient to Fund Operations at Least Through Mid-2017 ...
January 04, 2016 08:00 ET | Source: Chiasma, Inc.

Chiasma Expands Senior Management Team With Key Strategic Hires

NEWTON, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
November 30, 2015 08:00 ET | Source: Chiasma, Inc.

Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors

NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
November 12, 2015 16:01 ET | Source: Chiasma, Inc.

Chiasma Reports Third Quarter 2015 Financial Results and Recent Business Highlights

– Builds out infrastructure in advance of April 15, 2016 PDUFA target date – – EMA accepts Phase 3 trial design – – Conference call scheduled for 5 p.m. ET today...
November 11, 2015 08:00 ET | Source: Chiasma, Inc.

Chiasma to Present at Upcoming Investor Conferences

NEWTON, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...
October 29, 2015 08:00 ET | Source: Chiasma, Inc.

Chiasma to Report Third Quarter 2015 Financial Results on November 12

NEWTON, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for...